IFRX This is what Leerink had to say about the Ph2B HS trial: The Ph.IIb trial will be a randomized, double-blind, placebo-controlled, multicenter global study (~50 trial sites), which is expected to enroll ~175 patients (n=35/ cohort) with the aim of assessing the safety/ tolerability and efficacy of IFX-1 in HS patients as measured by the Hidradenitis Suppurativa Clinical Response (HiSCR) after 16 wks. of treatment. Unfortunately, I have nothing to add regarding trial design or comparitor(s),